Stephen Carter
Follow
Get notifications in MyBN when activity occurs.
Stephen Carter
Stephen Carter has over 25 years of pharmaceutical industry experience and has held a variety of senior positions with public listed companies including roles as both chairman and managing director. Mr Carter was chair of Hollista Colltech and DelMedica, and managing director of ASX-listed Solbec Pharmaceuticals. He has extensive contacts and experience in the financial markets and the pharmaceutical industry and is well equipped to lead executive management through the company's product commercialisation phase.
Lists and Charts
Total Shareholder Return as at 29/04/22
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 948th | Arovella Therapeutics | -3% | 12% |
| 1001st | Nanollose | -6% | |
| 1398th | 333D | -33% | -26% |
| 1443rd | FBR | -36% | -23% |
| 1908th | Ultima United | -88% | 17% |
1811 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 156th |  | Arovella Therapeutics | $1.2m |
| 173rd | | FBR | $497k |
| 174th | | 333D | $476k |
| 176th | | Nanollose | $323k |
| 178th | | Ultima United | $284k |
208 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
News Articles
Related Information
Positions - Previous
| Position | Company | Year | Company's current rank |
|---|---|---|---|
| Managing Director, Chief Executive | | 2010 - 2019 | 156 |
| Executive Chair | | 2018 - 2019 | 156 |
| Executive Chair | | 2012 - 2014 | 156 |
| Non-Executive Chair | | 2006 - 2009 | |
| Managing Director | | 2000 - 2006 | 402 |
| Non-Executive Director | | 2000 - 2006 | 402 |
Directors Interests
| Company | Date | Transaction type | Number of shares | Price per share | Transaction value | Nature of change |
|---|---|---|---|---|---|---|
| Arovella Therapeutics | 28 Jun 2019 | Issued | 2,261,110 | OtherProspectus | ||
| Arovella Therapeutics | 28 Jun 2019 | Issued | 4,522,222 | $0.00 | $18,089 | OtherProspectus |
| Arovella Therapeutics | 02 Aug 2018 | Issued | 6,083,333 | OtherIssue of options | ||
| Arovella Therapeutics | 02 Aug 2018 | Issued | 12,166,667 | $0.00 | $60,833 | OtherIssue of securities |
| Arovella Therapeutics | 02 Aug 2018 | Sold | 70,000 | $1.07 | $74,633 | OtherProspectus |
Powered by Morningstar ®
Equity Capital Markets Deals
| Date | Company | Transaction Type | Total Value | |
|---|---|---|---|---|
| 31/07/18 | Arovella Therapeutics | Placement + entitlement offer | $6.8m | >> |
| 20/01/14 | Arovella Therapeutics | Placement | $5.6m | >> |
| 30/03/15 | Arovella Therapeutics | Placement | $5.3m | >> |
| 26/06/19 | Arovella Therapeutics | Placement + entitlement offer | $3.9m | >> |
| 07/04/17 | Arovella Therapeutics | Placement | $1.5m | >> |
Mergers & Acquisitions Deals
| Announced | Bidder | Target | Transaction Type | Total Value | |
|---|---|---|---|---|---|
| 27/02/18 | Arovella Therapeutics | Asset acquisition | $1.7m | >> |
